Kilitch Drugs starts Rs. 100 crore New Facility Expansion Plan

Mukund Mehta, Chairman & Managing Director of Kilitch Drugs, said, "We are on a growth trajectory and demand for our products is increasing. This expansion will help us to fuel our growth plan."

Published On 2022-03-22 10:58 GMT | Update On 2022-03-22 10:58 GMT

New Delhi: Kilitch Drugs India Limited is a Leading MSME multinational manufacturer of Injectables in India and Ethiopia. Kilitch has purchased 15 Acres land parcel in Village: Maldev, Taluka: Pen, on Pen - Khopoli Highway, Maharashtra, as the beginning of its expansion plan.

The land bought by the company will be used for establishing a state-of-the-art greenfield pharma manufacturing complex. The company plans to set up 4-6 manufacturing units in different therapeutics categories to cater to the growing demands in Domestic and Exports markets.

The expansion will be in a similar line of products like Injectables and other Biotech products. The project envisaged is futuristic and shall have maximum recognition of the world's leading regulatory authorities.

Commenting on this Mukund Mehta, Chairman & Managing Director of Kilitch Drugs, said, "We are on a growth trajectory and demand for our products is increasing. This expansion will help us to fuel our growth plan. This will be an ultra-modern facility, and the capex requirement for this facility will be in tune of approx. Rs. 100 Crore.

We are planning to fund the capex mainly through internal accruals, and it will be in a phased manner. We are looking for a horizon of 2 years to commence commercial production of Phase I. Once the total expansion is complete, it will generate a Revenue opportunity of approx. Rs. 500 Crore."

Established in 1978, Kilitch Drug (India) is a successful pharmaceutical solution company. The company has a major focus in the African region and have a strong foothold across key African countries, with 350 products in 26 African countries.

The Company has a manufacturing plant located in Mumbai with a dedicated dry powder section and small volume liquid ampoules and vials. In 2018 the Company started a greenfield project in Ethiopia for Cephalosporins Injectables. The Company's manufacturing plants are certified by WHO, WHO GMP, ISO 9001, ISO 13845 etc.

The Company's strong clientele includes Intas, Mankind, Indoco Remedies, and a few.

For FY21 the Company has achieved Total Revenue of Rs. 74.21 crore with PAT of Rs. 6.16 crore.

Read Also - IIT Kharagpur to set up hub to tap MSMEs for affordable healthcare

Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Kilitch Drugs starts Rs. 100 crore New Facility Expansion Plan

Mukund Mehta, Chairman & Managing Director of Kilitch Drugs, said, "We are on a growth trajectory and demand for our products is increasing. This expansion will help us to fuel our growth plan."

Similar News

Torrent Pharma Slapped with Rs 41.33 Crore GST Penalty for Alleged Erroneous Export Refunds

Monocef NSQ Case: HC Rejects Aristo Labs Plea, Confirms Trial Before Magistrate

CDSCO Panel Clears Bristol Myers' Yervoy for Two New Cancer Indications

Indoco Remedies: President - Sales & Marketing Ajay Karajagi to retire

Jubilant Ingrevia ropes in Shilpa Sachdeva Bhullar as Vice President - Legal

Indian Pharmacopoeia Commission seals 3 major MoUs in Nagaland to boost drug safety

Emcure Pharma confirms GST Dept search operation, assures 'No Material Impact' on operations

Intas Pharma appoints Vijay Dabade as Associate Vice President - Quality Control